الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 159 |  |  |
| | | from | 159 | | |
Abstract
Polycystic ovary syndrome (PCOS) is a common endocrinopathy that affects 5–10% of women of reproductive age. Despite the development of universally accepted criteria for the diagnosis of the syndrome by the European Society for Human Reproduction (ESHRE) and the American Society of Reproductive Medicine (ASRM) (The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group, 2004).
in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) is the final step of treatment for PCOS patients with infertility. (Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group 2008).
However, controlled ovarian stimulation in these patients remains a challenge till date because of risk of potentially lethal complication like ovarian hyperstimulation syndrome (OHSS). (Delvigne 1993)
Different stimulation protocols have been suggested, but still there is no consensus as to which protocol is best for patients with PCOS. Gonadotropin-releasing hormone (GnRH) antagonist is being increasingly used in COS for IVF from late 1990s. GnRH antagonists do not require long desensitization as in agonist protocol and induce rapid reduction in the level of follicle stimulating hormone (FSH) and luteinizing hormone (LH) without initial flair up thus ensuring a short and simple IVF cycle and better patient compliance. Although there was initial reports that antagonist cycles were associated with lower ongoing pregnancy rate when compared to long agonist cycles. ( Tarlatzis et, al. 2003).